SS Innovations International (NASDAQ: SSII) announced that its SSi Mantra surgical robotic system will be featured at the 2026 Society of Robotic Surgery Annual Meeting, scheduled for July 23-26 in Hollywood, Florida. The system will be displayed throughout the event, highlighted in multiple breakout sessions, and used in a live broadcast of a remote partial nephrectomy performed by Dr. Amitabh Singh from the company's headquarters in Gurugram, India, on a patient at Rajeev Gandhi Cancer Institute and Research Centre in New Delhi.
Chairman and CEO Dr. Sudhir Srivastava will participate as a speaker and panelist in multiple sessions covering telesurgery, robotic surgery adoption, regulatory frameworks, and global access to robotic care. As of July 6, 2026, the SSi Mantra system had been used in 12,375 procedures spanning more than 170 procedure types, including 653 cardiac procedures, 178 telesurgeries, and 225 pediatric surgeries, while approximately 2,100 physicians have been trained on the platform.
The demonstration underscores the growing importance of telesurgery in expanding access to advanced surgical care. The live remote partial nephrectomy will showcase the system's capability to perform complex procedures across long distances, potentially reducing the need for patient travel and enabling specialist surgeons to operate on patients in underserved regions. This aligns with the company's vision of making robotic surgery affordable and accessible globally.
The SSi Mantra's presence at the Society of Robotic Surgery meeting signals its increasing acceptance within the surgical community. With over 12,000 procedures completed, including a significant number of cardiac and pediatric cases, the system is positioned as a versatile platform capable of handling a wide range of surgical specialties. The training of 2,100 physicians suggests a growing base of skilled users, which could accelerate adoption.
Dr. Srivastava's participation in regulatory and access discussions indicates the company's focus on navigating the complex landscape of medical device approval and reimbursement. As robotic surgery becomes more prevalent, establishing clear regulatory pathways and demonstrating cost-effectiveness will be critical for widespread adoption. The SSi Mantra, being a cost-effective alternative to established systems, may appeal to healthcare providers seeking to expand robotic surgery programs without the high capital expenditure.
The conference will also provide a platform for SS Innovations to network with potential partners, distributors, and clinicians, potentially paving the way for expanded market presence. The company's plans to expand globally hinge on such engagements, as well as on continued clinical evidence supporting the system's safety and efficacy.
For more information, the full press release is available at https://ibn.fm/YYYKE. The company's forward-looking statements and disclaimers are detailed on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
